이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

유방암 환자를 대상으로 복합 치료의 효능 및 안전성을 평가하는 연구

2026년 11월 2일 업데이트: Hoffmann-La Roche

유방암 환자(MORPHEUS-BREAST CANCER)에서 다중 치료 조합의 효능 및 안전성을 평가하는 Ib/II상, 공개 라벨, 다기관, 무작위 엄브렐러 연구

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population.

Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor-positive (ER+), HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting.

Cohort 2 will focus on inoperable, locally advanced or metastatic, ER+, HER2-positive breast cancer with previous progression to standard-of-care anti-HER2 therapies, of which one was a trastuzumab-and-taxane-based systemic therapy (including in the early setting if recurrence occurred within 6 months of finishing adjuvant therapy) and one was a HER2-targeting antibody-drug conjugate (ADC; e.g., ado-trastuzumab emtansine or trastuzumab-deruxtecan) or a HER2-targeting tyrosine kinase inhibitor (TKI; e.g., tucatinib, lapatinib, pyrotinib, or neratinib).

Cohort 3 will focus on inoperable, locally advanced or metastatic, ER+, HER2-negative, PIK3CA-mutated breast cancer with resistance to adjuvant endocrine therapy.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

316

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

연구 연락처 백업

  • 이름: Reference Study ID Number: CO42867 https://forpatients.roche.com/ No attachments to email below.
  • 전화번호: 888-662-6728 (U.S. Only)
  • 이메일: global-roche-genentech-trials@gene.com

연구 장소

      • Goyang-si, 대한민국, 10408
        • 모병
        • National Cancer Center
      • Seoul, 대한민국, 05505
        • 모병
        • Asan Medical Center
      • Seoul, 대한민국, 03080
        • 모병
        • Seoul National University Hospital
      • Seoul, 대한민국, (0)6351
        • 모병
        • Samsung Medical Center
      • Seoul, 대한민국, 3722
        • 모병
        • Severance Hospital
    • California
      • Duarte, California, 미국, 91010
        • 모병
        • City of Hope
      • Irvine, California, 미국, 92618-2377
        • 모병
        • City of Hope - Orange County Lennar Foundation Cancer Center
      • San Francisco, California, 미국, 94143
        • 모병
        • University of California, San Francisco (UCSF)
      • Santa Monica, California, 미국, 90404
        • 모병
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
      • Stanford, California, 미국, 94305
        • 모병
        • Stanford Cancer Institute (SCI)
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • 모병
        • Massachusetts General Hospital
    • New Jersey
      • Freehold, New Jersey, 미국, 07728
        • 빼는
        • Regional Cancer Care Associates LLC (RCCA) - Freehold Location
      • Howell Township, New Jersey, 미국, 07731
        • 빼는
        • Regional Cancer Care Associates LLC ? Howell Division
    • North Carolina
      • Charlotte, North Carolina, 미국, 28204
        • 모병
        • Levine Cancer Institute
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19107
        • 모병
        • Thomas Jefferson University Hospital
      • Pittsburgh, Pennsylvania, 미국, 15219
        • 빼는
        • University of Pittsburgh Cancer Institute
    • Tennessee
      • Germantown, Tennessee, 미국, 38138
        • 모병
        • West Cancer Center
      • Barcelona, 스페인, 08035
        • 모병
        • Hospital Universitario Vall d Hebron
      • Madrid, 스페인, 28050
        • 모병
        • Centro Integral Oncológico Clara Campal Ensayos Clínicos START
      • Madrid, 스페인, 28034
        • 모병
        • Hospital Universitario Ramón y Cajal
      • Valencia, 스페인, 46010
        • 모병
        • Hospital Clinico Universitario de Valencia
      • Haifa, 이스라엘, 3109601
        • 모병
        • Rambam Medical Center
      • Jerusalem, 이스라엘, 91120
        • 모병
        • Hadassah Ein Karem Hospital
      • Petah Tikva, 이스라엘, 4941492
        • 모병
        • Rabin MC
      • Ramat Gan, 이스라엘, 52621
        • 모병
        • The Chaim Sheba Medical Center
      • Tel Aviv, 이스라엘, 6423906
        • 모병
        • Tel Aviv Sourasky Medical Center
      • Tel Aviv, 이스라엘, 6971028
        • 모병
        • Assuta Medical Centers
    • Jerusalem
      • Jerusalem, Jerusalem, 이스라엘, 9103102
        • 모병
        • Shaare Zedek Medical Center
    • South Australia
      • Bedford Park, South Australia, 호주, 5042
        • 모병
        • Flinders Medical Centre
    • Victoria
      • Frankston, Victoria, 호주, 3199
        • 모병
        • Peninsula Health-Frankston Hospital
      • Melbourne, Victoria, 호주, 3000
        • 모병
        • Peter Maccallum Cancer Centre
    • Western Australia
      • Nedlands, Western Australia, 호주, 6009
        • 모병
        • Linear Clinical Research Limited

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

Inclusion Criteria for Cohort 1 (Stage 1 [and Stage 2, only where indicated]):

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Documented estrogen receptor-positive (ER+) tumor
  • Patients for whom endocrine therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines
  • Radiologic/objective evidence of recurrence or progression after the most recent systemic therapy for breast cancer
  • Disease progression during or after first- or second-line hormonal therapy for locally advanced or metastatic disease (note: at least one line of therapy must have contained a CDK4/6i administered for a minimum of 8 weeks prior to disease progression.)
  • Postmenopausal status for women
  • Life expectancy ≥3 months
  • Availability of a representative tumor specimen that is suitable for biomarker evaluation via central testing
  • Prior fulvestrant therapy is allowed
  • Stages 1 and 2: Measurable disease (at least one target lesion) according to RECIST v1.1
  • Stages 1 and 2: Adequate hematologic and end-organ function
  • Stages 1 and 2: Stable anticoagulant regimen for patients receiving therapeutic anticoagulation

Inclusion Criteria for Cohort 2 (Stage 1 [and Stage 2, only where indicated]):

  • ECOG Performance Status of 0 or 1
  • Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally advanced disease not amenable to curative resection
  • ER+, HER2-positive breast cancer
  • Postmenopausal status for women
  • Life expectancy ≥3 months
  • Willingness to have a representative tumor specimen that is suitable for biomarker evaluation via central testing submitted, if available
  • Prior endocrine therapy in the advanced setting allowed, including fulvestrant if given more than 28 days prior to randomization, but excluding other selective estrogen receptor degraders (SERDs)
  • Stages 1 and 2: Measurable disease (at least one target lesion) according to RECIST v1.1
  • Stages 1 and 2: Baseline left ventricular ejection fraction (LVEF) ≥50% as measured by ECHO or MUGA scans
  • Stages 1 and 2: Adequate hematologic and end-organ function
  • Stages 1 and 2: Stable anticoagulant regimen for patients receiving therapeutic anticoagulation

Inclusion Criteria for Cohorts 1 and 2 (Stage 2):

  • Ability to initiate Stage 2 treatment within 3 months after experiencing unacceptable toxicity, disease progression as determined by the investigator according to RECIST v1.1, or loss of clinical benefit as determined by the investigator, provided that a Stage 2 slot is available and patient meets eligibility criteria for Stage 2
  • Availability of a tumor specimen from a biopsy performed upon discontinuation of Stage 1 because of unacceptable toxicity to drugs, disease progression as determined by the investigator according to RECIST v1.1, or loss of clinical benefit as determined by the investigator

Inclusion Criteria for Cohort 3:

  • Measurable disease (at least one target lesion) according to RECIST v1.1
  • ECOG Performance Status of 0 or 1
  • Documented ER+ tumor
  • Patients for whom endocrine therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines
  • Histologically or cytologically confirmed and documented adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to surgical or radiation therapy with curative intent
  • Patients must have progressed during adjuvant endocrine treatment or within 12 months of completing adjuvant endocrine therapy with an aromatase inhibitor or tamoxifen. If a CDK4/6i was included as part of neoadjuvant or adjuvant therapy, progression event must be >12 months since completion of CDK4/6i portion of neoadjuvant or adjuvant therapy.
  • Postmenopausal status for women (including women on or starting luteinizing hormone-releasing hormone [LHRH] agonist for ovarian suppression prior to randomization)
  • Life expectancy ≥6 months
  • Adequate hematologic and end-organ function
  • Evidence of an eligible PIK3CA mutation based on pre-existing test results (i.e., previously obtained as part of clinical practice) from blood or tumor tissue. If pre-existing test results are not available, submission of a freshly collected pretreatment blood sample to determine PIK3CA mutation status at a central testing site with the FoundationOne Liquid® CDx assay is required.

Exclusion Criteria:

General Exclusion Criteria for all Treatment Arms in Stage 1, Cohorts 1 and 2 (unless only applicable to one cohort, as indicated):

  • Prior treatment with any of the protocol-specified study treatments
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Systemic treatment for breast cancer within 2 weeks of Cycle 1, Day 1 or 5 half-lives of the drug prior to Cycle 1, Day 1
  • Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization
  • Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1 or better, with the exception of alopecia of any grade and Grade ≤2 peripheral neuropathy
  • Eligible only for the control arm
  • Prior allogeneic stem cell or solid organ transplantation
  • Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study
  • History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Uncontrolled tumor-related pain
  • Uncontrolled or symptomatic hypercalcemia
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • History of leptomeningeal disease
  • Active tuberculosis
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
  • Active cardiac disease or history of cardiac dysfunction
  • Positive HIV test at screening or at any time prior to screening
  • Active Hepatitis B or Hepatitis C virus infection
  • Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major upper gastrointestinal (GI) surgery, including gastric resection, potentially affecting enteral absorption
  • Known allergy or hypersensitivity to any of the study drugs or any of their excipients
  • Cohort 1 only: Known HER2-positive breast cancer
  • Cohort 1 only: Concurrent hormone replacement therapy
  • Cohort 1 only: Prior treatment with cytotoxic chemotherapy for metastatic breast cancer (with the exception of single agent capecitabine, which will count as a single line of therapy)
  • Cohort 2 only: Dyspnea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy
  • Cohort 2 only: Current chronic daily treatment (continuous for >3 months) with corticosteroids (dose of 10 mg/day methylprednisolone equivalent), excluding inhaled steroids

Additional Exclusion Criteria for Giredestrant + Abemaciclib Arm and Giredestrant + Abemaciclib + Atezolizumab Arm (Cohort 1, Stage 1):

  • Interstitial lung disease or severe dyspnea at rest or requiring oxygen therapy
  • History of major surgical resection involving the stomach or small bowel, or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea
  • History of syncope of cardiovascular etiology, ventricular arrhythmia, or sudden cardiac arrest

Additional Exclusion Criteria for Giredestrant + Ipatasertib Arm (Cohort 1, Stage 1):

  • Prior treatment with an Akt inhibitor
  • Inability to swallow medication or malabsorption condition that would alter the absorption of orally administered medications
  • Grade ≥2 uncontrolled or untreated hypercholesterolemia or hypertriglyceremia
  • History of Type 1 or Type 2 diabetes mellitus requiring insulin
  • History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion

Additional Exclusion Criteria for the Giredestrant + Inavolisib and Giredestrant + Inavolisib (ESR1m enriched) Arms (Cohort 1, Stage 1):

  • Prior treatment with any PI3K, Akt, or mTOR inhibitor, or any agent whose mechanism of action is to inhibit the PI3K/Akt/mTOR pathway
  • Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
  • Fasting glucose ≥126 mg/dL or ≥7.0 mmol/L and HbA1c ≥5.7% (or HbA1c ≥6.4% for the ESR1m enriched Arm only)
  • Any concurrent ocular or intraocular condition, excluding baseline cataracts, that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss
  • Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye
  • Symptomatic active lung disease, including pneumonitis
  • Inability to confirm biomarker eligibility based on valid results from either central testing of blood or local testing of blood or tumor tissue that documents one of the protocol-defined PIK3CA mutations
  • ESR1m enriched Arm only: Inability to determine ESR1 mutation status based on valid results from either central testing of blood or from pre-existing test results (from blood or tumor tissue) that confirm the presence of an ESR1 mutation. While patients who have tumors without detectable ESR1 mutation may be enrolled in this arm, a pre-existing test with no detectable ESR1m result is not acceptable for enrollment, and the participant in this case must submit a sample for central testing.

Additional Exclusion Criteria for Giredestrant + Ribociclib Arm (Cohort 1, Stage 1):

  • Currently receiving or has received systemic corticosteroids ≤2 weeks prior to starting trial treatment
  • Impairment of GI function or GI disease that may significantly alter the absorption of the oral trial treatments

Additional Exclusion Criteria for Giredestrant + Samuraciclib Arm (Cohort 1, Stage 1):

  • Prior treatment with mTOR inhibitor
  • Receipt of systemic corticosteroids (at a dose >10 mg prednisone/day or equivalent) within 14 days before the first dose of samuraciclib
  • Active bleeding diatheses
  • History of hemolytic anemia or marrow aplasia
  • Receipt of a live-virus vaccination within 28 days or less of planned treatment start

Additional Exclusion Criteria for Giredestrant + Atezolizumab-Containing Arms (Cohort 1, Stage 1):

  • Active or history of autoimmune disease or immune deficiency
  • Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
  • Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodies
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Pregnant or breastfeeding, or intending to become pregnant during study treatment or within 5 months for atezolizumab

Additional Exclusion Criteria for Giredestrant + PH FDC SC + Abemaciclib Arm (Cohort 2, Stage 1):

  • Interstitial lung disease or severe dyspnea
  • History of major surgical resection involving the stomach or small bowel, preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea, or a condition that may significantly alter the absorption of the oral trial treatments
  • History of syncope of cardiovascular etiology, ventricular arrhythmia, or sudden cardiac arrest

Additional Exclusion Criteria for Giredestrant + PH FDC SC + Palbociclib Arm (Cohort 2, Stage 1):

  • History of major surgical resection involving the stomach or small bowel, preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea, or a condition that may significantly alter the absorption of the oral trial treatments
  • Interstitial lung disease or severe dyspnea

Exclusion Criteria for Cohort 3:

  • Known HER2-positive breast cancer
  • Prior treatment with any SERD (e.g., fulvestrant, novel oral), proteolysis targeting chimera, complete ER antagonist (CERAN), or novel SERM (other than tamoxifen, toremifene)
  • Prior treatment with any PI3Kalpha (PIK3CA gene product), AKT or mTOR inhibitor
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization
  • Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1 or better, with the exception of alopecia of any grade and Grade ≤2 peripheral neuropathy
  • Major surgical procedure within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study
  • History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Uncontrolled tumor-related pain
  • Uncontrolled or symptomatic hypercalcemia
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • History of leptomeningeal disease
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Treatment for clinically significant infection with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
  • Active cardiac disease or history of cardiac dysfunction
  • Positive HIV test at screening or at any time prior to screening
  • Active Hepatitis B or Hepatitis C virus infection
  • Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major upper gastrointestinal (GI) surgery, including gastric resection, potentially affecting enteral absorption
  • Known allergy or hypersensitivity to any of the study drugs or any of their excipients

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: 코호트 1: 지레데스트란트 단일요법

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171
실험적: 집단 1: Giredestrant + 아베마시클립

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • 버제니오™
실험적: 코호트 1: Giredestrant + Ipatasertib

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-0068
  • RG7440
  • RO5532961
실험적: 코호트 1: 기레데스트란트 + 이나볼리십

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-0077
  • RG6114
  • RO7113755
  • ITOVEBI™
실험적: 집단 1: Giredestrant + Ribociclib

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • 키스칼리®
실험적: 코호트 1: 기레데스트란트 + 에베로리무스

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • 아피니토®
실험적: 코호트 1: Giredestrant + Samuraciclib

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • ICEC0942
  • CT7001
실험적: 코호트 1: 지레데스트란트 + 아테졸리주맙

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.

다른 이름들:
  • RO5541267
  • 티센트릭®
  • RG7446
실험적: 코호트 1: 기레데스트란트 + 아베마시클립 + 아테졸리주맙

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • 버제니오™

840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.

다른 이름들:
  • RO5541267
  • 티센트릭®
  • RG7446
활성 비교기: 코호트 2: 지레데스트란트 + PH FDC SC

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.

다른 이름들:
  • 페스고™
  • RG6264
  • RO7198574
  • 페르투주맙, 트라스투주맙 및 히알루로니다아제-zzxf
실험적: 코호트 2: 기레데스트란트 + PH FDC SC + 아베마시클립

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • 버제니오™

On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.

다른 이름들:
  • 페스고™
  • RG6264
  • RO7198574
  • 페르투주맙, 트라스투주맙 및 히알루로니다아제-zzxf
실험적: 코호트 2: 기레데스트란트 + PH FDC SC + 팔보시클립

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.

다른 이름들:
  • 페스고™
  • RG6264
  • RO7198574
  • 페르투주맙, 트라스투주맙 및 히알루로니다아제-zzxf

125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • 입랜스®
실험적: 코호트 3 : Giredestrant + inavolisib + palbociclib

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-0077
  • RG6114
  • RO7113755
  • ITOVEBI™

125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • 입랜스®
실험적: 코호트 3 : Giredestrant + inavolisib + Abemaciclib

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • 버제니오™

9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-0077
  • RG6114
  • RO7113755
  • ITOVEBI™
실험적: 코호트 3 : Giredestrant + inavolisib + ribociclib

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-0077
  • RG6114
  • RO7113755
  • ITOVEBI™

600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • 키스칼리®
실험적: Cohort 1: Giredestrant + Inavolisib (ESR1m enriched)

ESR1m stands for estrogen receptor mutation.

30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-9545
  • RO7197597
  • RG6171

9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

다른 이름들:
  • GDC-0077
  • RG6114
  • RO7113755
  • ITOVEBI™

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
고형 종양의 반응 평가 기준, 버전 1.1(RECIST v1.1)에 따라 조사자가 결정한 대로 완전 또는 부분 반응으로 정의된 객관적 반응을 가진 참가자의 백분율
기간: 기준선에서 질병 진행까지(최대 6년)
기준선에서 질병 진행까지(최대 6년)
부작용이 있는 참가자 수, 미국 국립암연구소(National Cancer Institute Common Terminology Criteria for Adverse Events) 버전 5.0(NCI CTCAE v5.0)에 따라 심각도가 결정됨
기간: 기준선부터 연구 약물의 마지막 투여 후 30일까지(최대 6년)
기준선부터 연구 약물의 마지막 투여 후 30일까지(최대 6년)

2차 결과 측정

결과 측정
기간
RECIST v1.1에 따라 연구자가 결정한 무진행 생존
기간: 무작위배정부터 질병 진행이 처음으로 기록된 날짜 또는 모든 원인으로 인한 사망 중 먼저 발생하는 날짜까지(최대 6년)
무작위배정부터 질병 진행이 처음으로 기록된 날짜 또는 모든 원인으로 인한 사망 중 먼저 발생하는 날짜까지(최대 6년)
RECIST v1.1에 따라 조사자가 결정한 바와 같이 12주 이상 동안 안정적인 질병 또는 완전 또는 부분 반응을 보이는 참가자의 백분율로 정의되는 질병 통제율
기간: 기준선에서 질병 진행까지(최대 6년)
기준선에서 질병 진행까지(최대 6년)
RECIST v1.1에 따라 연구자가 결정한 대로 ≥24주 동안 안정적인 질병이 있거나 확인된 완전 또는 부분 반응이 있는 참가자의 백분율로 정의되는 임상적 이점률
기간: 기준선에서 질병 진행까지(최대 6년)
기준선에서 질병 진행까지(최대 6년)
전반적인 생존
기간: 무작위 배정에서 모든 원인으로 인한 사망까지(최대 6년)
무작위 배정에서 모든 원인으로 인한 사망까지(최대 6년)
RECIST v1.1에 따라 조사자가 결정한 응답 기간
기간: 문서화된 객관적 반응의 첫 번째 발생부터 기록된 질병 진행의 첫 번째 날짜 또는 모든 원인으로 인한 사망 중 먼저 발생하는 날짜까지(최대 6년)
문서화된 객관적 반응의 첫 번째 발생부터 기록된 질병 진행의 첫 번째 날짜 또는 모든 원인으로 인한 사망 중 먼저 발생하는 날짜까지(최대 6년)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Clinical Trials, Hoffmann-La Roche

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 6월 22일

기본 완료 (추정된)

2029년 5월 30일

연구 완료 (추정된)

2029년 5월 30일

연구 등록 날짜

최초 제출

2021년 3월 15일

QC 기준을 충족하는 최초 제출

2021년 3월 16일

처음 게시됨 (실제)

2021년 3월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CO42867
  • 2020-004889-19 (EudraCT 번호)
  • 2023 (미국 NIH 보조금/계약)
  • 2023-507495-48-00 (씨티스)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .